Biblio

Author Title [ Type

] Year

Filters: Author is Li, Weiming [Clear All Filters]

Journal Article

Li Q, Zhong Z, Zeng C, Meng L, Li C, Luo Y, Wang H, Li W, Wang J, Cheng F, et al. A clinical observation of Chinese chronic myelogenous leukemia patients after discontinuation of tyrosine kinase inhibitors. Oncotarget. 2016.

Zhang X, Xu N, Yang Y, Lin H, Liu B, Du X, Liu X, Liang R, Chen C, Huang J, et al. Comparison of the Efficacy Among Nilotinib, Dasatinib, Flumatinib and Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Patients: A Real-World Multi-Center Retrospective Study. Clin Lymphoma Myeloma Leuk. 2024.

Jiang Q, Li Z, Qin Y, Li W, Xu N, Liu B, Zhang Y, Meng L, Zhu H, Du X, et al. Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial. J Hematol Oncol. 2023;16(1):13.

Fang J, Zhang R, Wang H, Hong M, Wu Q, Nie D, You Y, Zhong Z, Li W, Hu Y, et al. Idarubicin-intensified BUCY2 conditioning regimen improved survival in high-risk acute myeloid, but not lymphocytic leukemia patients undergoing allogeneic hematopoietic stem cell transplantation: A retrospective comparative study. Leuk Res. 2016;46:61-68.

Zhang X, Gale RPeter, Liu B, Huang J, Zhang Y, Du X, Weng J, Li W, Xu N, Liu X, et al. Validation of the imatinib-therapy failure model. Leukemia. 2023.